Medullary Aplasia Revealing a Metastatic Prostatic Adenocarcinoma | Zendy

Idriss Ziani | Zendy; Ahmed Ibrahimi | Zendy; Omar Bellouki | Zendy; Youssef Zaoui | Zendy; Yasmine Laraqui Housseini | Zendy; Fouad Zouidia | Zendy; Hachem El Sayegh | Zendy; Lounis Benslimane | Zendy; Yassine Nouini | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Medullary Aplasia Revealing a Metastatic Prostatic Adenocarcinoma

Author(s) -

Idriss Ziani,

Ahmed Ibrahimi,

Omar Bellouki,

Youssef Zaoui,

Yasmine Laraqui Housseini,

Fouad Zouidia,

Hachem El Sayegh,

Lounis Benslimane,

Yassine Nouini

Publication year - 2021

Publication title -

case reports in urology

Language(s) - English

Resource type - Journals

eISSN - 2090-696X

pISSN - 2090-6978

DOI - 10.1155/2021/8898130

Subject(s) - medicine , pancytopenia , pallor , anemia , prostate cancer , bone marrow , anorexia , leukopenia , biopsy , medullary cavity , prostate , gastroenterology , pathology , cancer , toxicity

In this case report, we are reporting the case of a 68-year-old male patient who was admitted in our hospital for unintended weight loss, asthenia, and anorexia. Physical examination showed clinical signs of anemia such as pallor of skin and mucous membranes; hemodynamic parameters were normal. Complete blood count (CBC) analysis showed a pancytopenia with anemia, thrombocytopenia, and leukopenia. BM biopsy was performed, showing a malignant infiltration of bone marrow by a metastatic prostate cancer confirmed by immunohistochemistry. Prostate biopsy confirmed the diagnosis of acinar adenocarcinoma with Gleason score 8 (4 + 4), ISUP grade group 4. Our patient underwent chemical castration using LH-RH analogs in association with second-line hormone therapy by abiraterone acetate. The evolution was good on both the oncological and hematological levels.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research